Skip to content

Fluid Balance During Surgery for Ovarian Cancer

Intraoperative Fluid Balance During Cytoreductive Surgery for Ovarian Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03006939
Enrollment
60
Registered
2016-12-30
Start date
2016-12-31
Completion date
2022-12-31
Last updated
2016-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fluid Therapy, Ovarian Neoplasm

Brief summary

Extensive tumour debulking challenges both surgeon and anaesthesiologist but promotes survival in late-stage ovarian cancer patients. Little is known about the intraoperative fluid balance and its impact on morbidity and mortality.

Interventions

PROCEDURECytoreductive surgery

Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival

Sponsors

University Hospital, Bonn
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients scheduled for cytoreductive surgery in ovarian cancer

Exclusion criteria

* Age \< 18 years * unability to give consent

Design outcomes

Primary

MeasureTime frameDescription
fluid balanceat the end of surgeryintraoperative fluid balance is determined by the difference between fluid intake and outtake

Secondary

MeasureTime frameDescription
mechanical ventilationat the timepoint of extubationDuration of mechanical ventilation, starting from endotracheal intubation until extubation
mortality5 yearslong-term mortality after surgery

Countries

Germany

Contacts

Primary ContactMartin Soehle, MD, PhD
martin.soehle@ukb.uni-bonn.de0049-228-287-

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026